PALI
Palisade Bio, Inc.
1W: +1.5%
1M: +11.7%
3M: -3.9%
YTD: -20.0%
1Y: +185.3%
3Y: -92.3%
5Y: -100.0%
$1.96
-0.04 (-2.00%)
After Hours: $1.98 (+0.02, +1.02%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$298.0M
52W Range0.53-2.64
Volume4,490,138
Avg Volume4,421,662
Beta1.55
Dividend—
Analyst Ratings
Company Info
CEOJ. D. Finley
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2007-03-30
Websitepalisadebio.com
5800 Armada Drive
Carlsbad, CA 92008
US
Carlsbad, CA 92008
US
858 704 4900
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Latest News
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Jones Mitchell Lawre | S-Sale | 1,989 | $1.75 | 2026-02-12 |
| Finley John David | S-Sale | 3,896 | $1.75 | 2026-02-12 |
| Jones Mitchell Lawre | M-Exempt | 8,000 | — | 2026-02-11 |
| Jones Mitchell Lawre | M-Exempt | 8,000 | — | 2026-02-11 |
| Finley John David | M-Exempt | 13,333 | — | 2026-02-11 |